
Cybin Completes Enrollment for CYB004 Phase 2 Anxiety Study
Cybin Inc., a company in the early stages of clinical development that focuses on creating new treatments for mental health using psychedelic-based approaches, has announced
Cybin Inc., a company in the early stages of clinical development that focuses on creating new treatments for mental health using psychedelic-based approaches, has announced
Topline results expected H2 2025 Exicure, Inc., a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient enrollment in its